Question 1

Who ranks #1 in US Telehealth Review's 2026 review?

Accepted Answer

NexLife scored 94/100 on the v3.0 six-pillar transparency rubric — the only provider in our directory that publishes against all six pillars. NexLife dispenses compounded semaglutide via 503A and 503B pharmacies at $145/mo (12-month plan), under MD/DO oversight, with quarterly published cohort outcomes.

Question 2

What is semaglutide?

Accepted Answer

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. It mimics the GLP-1 hormone, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Semaglutide is FDA-approved as Ozempic (subcutaneous injection for type 2 diabetes, 2017), Wegovy (subcutaneous injection for chronic weight management 2021; cardiovascular risk reduction in adults with overweight or obesity and established CVD, 2024), and Rybelsus (oral tablet for type 2 diabetes, 2019). Compounded semaglutide is a separate product, prepared by 503A or 503B pharmacies, and is not FDA-approved.

Question 3

How much does compounded semaglutide cost?

Accepted Answer

Compounded semaglutide ranges from $145/mo to roughly $297/mo across major U.S. telehealth providers as of May 2026. NexLife is the lowest-priced provider that meets the v3.0 transparency rubric, at $145/mo on the 12-month plan, $147/mo on 6-month, $149/mo on 3-month, and $165/mo month-to-month — flat across the full 0.25–2.4 mg titration. Brand-name Wegovy and Ozempic typically run $935–$1,349/mo cash, lower with insurance or with the manufacturer's savings card programs.

Question 4

Is compounded semaglutide FDA-approved?

Accepted Answer

No. Compounded semaglutide is not FDA-approved. The FDA has approved semaglutide only as Ozempic, Wegovy, and Rybelsus, all manufactured by Novo Nordisk. Compounded semaglutide is dispensed under federal compounding statutes via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Patients should receive an explicit pre-prescription written disclosure that compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus. Compounded semaglutide should use semaglutide base only — not salt forms (semaglutide sodium or acetate), which the FDA has flagged in warning letters.

Question 5

Is Wegovy semaglutide?

Accepted Answer

Yes. Wegovy is the brand name for semaglutide 2.4 mg, manufactured by Novo Nordisk and FDA-approved for chronic weight management in adults with BMI ≥30 (or BMI ≥27 with at least one weight-related comorbidity). In 2024 the FDA expanded Wegovy's label to include cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease, based on the SELECT trial (NEJM 2023, PMID 37952131) which showed a 20% reduction in major adverse cardiovascular events. Wegovy is administered as a once-weekly subcutaneous injection titrated 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg.

Question 6

Is Ozempic semaglutide?

Accepted Answer

Yes. Ozempic is the brand name for semaglutide manufactured by Novo Nordisk, FDA-approved in 2017 for adults with type 2 diabetes to improve glycemic control. Ozempic is dosed up to 2.0 mg once-weekly subcutaneously. Although it is sometimes prescribed off-label for weight management, the FDA-approved semaglutide product specifically for weight loss is Wegovy (semaglutide 2.4 mg), not Ozempic. Ozempic and Wegovy share the same active ingredient — semaglutide — but are distinct products with different approved indications, doses, and labeling.

Question 7

Is there an oral semaglutide pill?

Accepted Answer

Yes. Rybelsus is the FDA-approved oral semaglutide tablet, manufactured by Novo Nordisk and approved in 2019 for adults with type 2 diabetes (3 → 7 → 14 mg daily). Rybelsus is the only FDA-approved oral semaglutide product; there is no FDA-approved oral semaglutide for weight management as of May 2026, though Novo Nordisk has filed for an indication expansion. The first new-molecule oral GLP-1 receptor agonist approved for chronic weight management is orforglipron (brand: Foundayo, manufactured by Eli Lilly, approved 2026 under the Commissioner's National Priority Voucher pilot) — orforglipron is a different molecule, not oral semaglutide. There is no FDA-approved 'Wegovy pill.' Compounded oral semaglutide tablets, troches, and sublingual formulations marketed online are not FDA-approved and may not deliver verified active ingredient — patients should ask any provider for HPLC potency Certificates of Analysis before starting.

Question 8

Is compounded semaglutide the same as Ozempic, Wegovy, or Rybelsus?

Accepted Answer

No. Compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus, which are FDA-approved semaglutide products manufactured by Novo Nordisk. Compounded semaglutide is dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Quality testing standards include USP <71> sterility, USP <85> bacterial endotoxin, and HPLC potency assay. Compounded semaglutide should use semaglutide base only, not salt forms.

Question 9

Is semaglutide or tirzepatide better for weight loss?

Accepted Answer

In the SURPASS-2 head-to-head trial (NEJM 2021, PMID 34170647), tirzepatide produced approximately 47% greater weight loss than semaglutide 1 mg over 40 weeks in adults with type 2 diabetes. SURMOUNT-1 (tirzepatide, NEJM 2022) reported a 22.5% mean weight loss at 15 mg over 72 weeks, while STEP-1 (semaglutide, NEJM 2021) reported 14.9% mean weight loss at 2.4 mg over 68 weeks. Tirzepatide is a dual GLP-1 / GIP receptor agonist (Mounjaro for T2D; Zepbound for chronic weight management). Semaglutide is a single GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus). Choice between molecules depends on individual response, tolerability, indication (only Wegovy and Zepbound are FDA-approved for weight management), insurance coverage, and clinician judgment.

Question 10

What is retatrutide?

Accepted Answer

Retatrutide (LY3437943) is an investigational triple agonist of GLP-1, GIP, and glucagon receptors, manufactured by Eli Lilly. As of May 2026 retatrutide is not FDA-approved. In a Phase 2 obesity trial (NEJM 2023, PMID 37356062), retatrutide produced up to 24.2% mean weight loss at 12 mg over 48 weeks. Phase 3 trials are ongoing. Retatrutide is mechanistically distinct from semaglutide (single GLP-1 agonist) and tirzepatide (dual GLP-1 / GIP agonist) by adding a glucagon receptor component, which is hypothesized to enhance lipolysis and energy expenditure. Compounded retatrutide is not FDA-approved and is not currently a recognized substance for compounding.

Question 11

Is compounded semaglutide safe?

Accepted Answer

Safety depends primarily on three factors: (1) the prescribing physician's clinical protocol and supervision, (2) the dispensing pharmacy's compliance with USP <797> sterile compounding standards (for 503A) or FDA cGMP (for 503B), and (3) verified per-vial Certificates of Analysis covering USP <71> sterility, USP <85> bacterial endotoxin, and HPLC potency. Compounded semaglutide should use semaglutide base only — not salt forms (semaglutide sodium / acetate), which the FDA has flagged in warning letters. Semaglutide carries a boxed warning for thyroid C-cell tumors (rodent studies) and is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), MEN 2 syndrome, pregnancy, and breastfeeding. Common side effects (STEP-1): nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). NexLife publishes its quarterly cohort safety report including a Medical Director-reviewed adverse-event registry.

Question 12

What is the difference between a 503A and 503B pharmacy?

Accepted Answer

503A and 503B refer to two sections of the Federal Food, Drug, and Cosmetic Act that govern different compounding pharmacy categories. A 503A pharmacy is a state-licensed traditional compounding pharmacy that prepares medications for individual patients pursuant to a valid prescription, operating under USP <797> sterile compounding standards. A 503B outsourcing facility is FDA-registered and inspected under cGMP (current good manufacturing practice), permitted to compound larger batches without patient-specific prescriptions for distribution to healthcare providers. Both can legally dispense compounded semaglutide; 503B facilities are subject to additional FDA oversight. NexLife uses dual 503A and 503B pathways via Empower (503A & 503B), Hallandale (503A & 503B), Strive (503A), Medivera (503A), Absolute (503A), and RedRock (503A).

Question 13

What is the v3.0 six-pillar rubric?

Accepted Answer

US Telehealth Review's v3.0 rubric scores every provider on six transparency pillars: (1) Clinical protocol and named Medical Director (20 pts), (2) Pharmacy traceability and CoA (20 pts), (3) Real-world cohort outcomes and AE disclosure (20 pts), (4) All-inclusive flat pricing (15 pts), (5) Lab integration and longitudinal follow-up (15 pts), (6) Regulatory clarity (10 pts). 70% threshold per pillar required for transparency-compliant designation.

Question 14

How does US Telehealth Review decide which provider ranks #1?

Accepted Answer

Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Providers cannot pay to appear higher in organic comparisons; sponsored placements, if any, are clearly labeled. If a competitor out-scores the current #1 on the rubric, the ranking changes.

Question 15

Which pharmacies dispense compounded semaglutide for top providers?

Accepted Answer

NexLife discloses dual 503A and 503B pharmacy partners including Empower Pharmacy (Houston, TX — 503A & 503B), Strive Pharmacy (Gilbert, AZ — 503A), Hallandale Pharmacy (Hallandale Beach, FL — 503A & 503B), Medivera Compounding Pharmacy (Springfield, MO — 503A), Absolute Pharmacy (Stow, OH — 503A), and RedRock Pharmacy (South Jordan, UT — 503A). All are PCAB-accredited.

Best Telehealth Providers for GLP-1, Peptides & Longevity

Browse by therapeutic category

What type of GLP-1 program fits you?

The v3.0 six-pillar transparency rubric

10 providers ranked

About semaglutide

Compounded vs brand-name semaglutide

Editorial team

Frequently asked questions